Relevant research showed, trametinib combined with PI3K/mTOR dual inhibitor dactylitis can eliminate the enhancement of nuclear receptor related-1 protein (Nurr1) to cervical cancer cell aggressiveness by upregulating p21 and p27 expression and inhibiting MMP9 and KLF4 expression (Wan et al., 2021). This evidence concerns the gene KLF4 and cervical carcinoma.